Igantet

Human Tetanus Immunoglobulin, the active ingredient in Igantet, is a human immunoglobulin presented as an injection solution for intramuscular administration. It supplies anti‑tetanus antibodies that neutralize tetanus toxin, providing passive immunity for individuals at risk of tetanus and for patients with established tetanus infection.

GNH USA supplies Igantet as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide in accordance with EU quality standards. The company ensures appropriate cold‑chain storage and regulatory compliance for each shipment.

Igantet, a human tetanus immunoglobulin, is used within the tetanus immune globulin class for passive immunization against tetanus toxin.

- Prophylaxis of tetanus: Provides immediate protection for individuals with uncertain vaccination status or with dirty wounds. - Treatment of tetanus infection: Supplies antibodies to neutralize toxin in patients diagnosed with tetanus. - Post‑exposure management: Administered after injuries that pose a high risk of tetanus when active immunization is insufficient.

Igantet may be associated with adverse reactions following intramuscular administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Redness or swelling: localized erythema around the injection. - Fever: transient low‑grade temperature elevation. - Headache: mild to moderate headache occurring shortly after dosing. - Nausea: occasional feeling of queasiness. - Malaise: general sense of fatigue or weakness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Serum sickness‑like reaction: fever, rash, arthralgia occurring days after injection. - Severe allergic response: urticaria, bronchospasm, hypotension. - Hemolysis: destruction of red blood cells leading to anemia. - Aseptic meningitis: inflammation of meninges without infection. - Thrombophlebitis: inflammation of a vein at the injection site.

When using Igantet, several precautions should be observed to ensure safety and efficacy.

- Assess tetanus immunization history: verify prior vaccination status before use. - Screen for hypersensitivity: avoid in patients with known IgG allergy. - Use with caution in immunocompromised patients: monitor for reduced efficacy. - Avoid concurrent administration with live vaccines: may interfere with immune response. - Observe for signs of anaphylaxis: have emergency equipment ready. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igantet can interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid): - Concurrent use of other tetanus antitoxins: may cause excess antibody load. - Immunoglobulin products with different specificities: risk of immune complex formation. - Live attenuated vaccines administered within 4 weeks: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: injection may increase bleeding risk at site. - Corticosteroids: may diminish antibody activity. - Blood products: may interfere with immunoglobulin levels.